Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
May 08, 2026
TickeronGET DAILY SIGNALS
iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

Key Takeaways

  • IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures.
  • Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.
  • Top holdings like ISRG and EW contributed significantly to the downside, while gains in ABT and SYK provided limited offset.
  • Higher interest rates and sector rotation away from growth-oriented healthcare stocks weighed on performance.
  • Fund flows showed net outflows over the past year, reflecting reduced investor interest in the niche medical devices theme.

Understanding IHI and Its Portfolio Focus

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, offering targeted exposure to U.S. companies that manufacture and distribute medical devices, including imaging equipment, prosthetics, and surgical tools. It holds about 52 stocks, with the top 10 making up over 75% of assets. Key positions include ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is entirely allocated to healthcare, zeroing in on the medical devices subsector. This focus makes IHI particularly sensitive to industry challenges like reduced hospital spending and procedural delays, which has amplified its recent declines relative to more diversified healthcare ETFs.

IHI's Recent Price Action: 30 Days and Quarterly View

In the last 30 days, IHI fell from around $54.35 to $49.77, marking a -8.5% decline. The path was volatile and downward-trending, with sharp drops in late April speeding up the selloff. Over the past quarter, the retreat was even steeper at -15% from near $58.50 levels, driven by steady erosion amid broader market shifts. These moves line up with trailing returns of -4.3% for the prior month and -14.9% for three months as of early May, pointing to a bearish, range-bound pattern with lower highs. From what I see, this confirms ongoing pressure in the space.

Key Drivers Behind IHI's 30-Day Decline

The ETF's downturn over the past 30 days came mainly from weakness in its largest holdings and sector headwinds. Top holding ISRG dropped over 2%, pulling IHI lower given its 16.5% weight, while EW (Edwards Lifesciences) slid on concerns about cardiac device demand. Gains in ABT (up significantly) and SYK offered some cushion, but the portfolio's concentration magnified the losses. Softer demand for implants and neurotechnology—evident in Stryker's Q1 earnings miss—added to the strain. On the macro side, high interest rates raised financing costs for growth-reliant medtech companies, spurring profit-taking. Net fund outflows and a shift in sentiment toward value sectors only intensified the pressure. I also checked this using Tickeron’s AI Screener to gauge how IHI stacks up against peers.

Factors Shaping IHI's Quarterly Performance

The -15% quarterly slide built from mounting pressures on medical devices, including stretched valuations after 2025 gains and tighter macro conditions. Holdings like ISRG and EW lagged due to slower procedural growth and supply chain hurdles, while higher rates discounted future cash flows for innovation-focused firms. Earnings from peers like Stryker showed weaker demand in orthopedics and surgery, diverging from broader healthcare strength. Institutional outflows reached hundreds of millions over the year, with assets under management shrinking from $3.5B+ peaks, signaling fading confidence. Longer-term issues like hospital budget limits and rotation to cyclicals deepened the underperformance against health benchmarks. One thing that stands out is how these dynamics have persisted.

Why I Rely on Tickeron’s AI Screener for ETF Analysis

In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and performance metrics, surfacing trade ideas, breakouts, and opportunities faster than manual methods. This has been invaluable for tracking sector performance and dynamic ETF moves like those in medical devices. I’m watching it closely for the next insights.

Looking Ahead for IHI: Key Factors to Monitor

Looking forward, keep an eye on demand signals in medical devices, such as hospital procedure volumes and Q2 earnings from leaders like SYK and ISRG. The macro backdrop—Federal Reserve rate decisions and inflation—will shape valuations for growth names. Major holdings' progress in areas like robotic surgery adoption matters too. Supply chain stability and regulatory shifts could also influence the ETF. Risks persist from extended weak demand or outflows, but improved flows or rate cuts might aid a rebound. This is important because it frames the potential path.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: IHI

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


IHI in upward trend: price rose above 50-day moving average on October 15, 2026

IHI moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on IHI as a result. In 70 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for IHI just turned positive on October 08, 2026. Looking at past instances where IHI's MACD turned positive, the stock continued to rise in 44 of 53 cases over the following month. The odds of a continued upward trend are 83%.

Following a +0.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHI advanced for three days, in 232 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for IHI moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

IHI broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IHI entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC. The index includes medical equipment companies, including manufacturers and distributors of medical devices such as magnetic resonance imaging scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Medical Devices ETF (IHI) ETF is 20.49B. The market cap for tickers in the group ranges from 396.74M to 173.92B. ABT holds the highest valuation in this group at 173.92B. The lowest valued company is OFIX at 396.74M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was 16%. For the same ETF, the average monthly price growth was 23%, and the average quarterly price growth was 129%. NVCR experienced the highest price growth at 13%, while IART experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was -13%. For the same stocks of the ETF, the average monthly volume growth was 11% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 53
Price Growth Rating: 46
SMR Rating: 77
Profit Risk Rating: 90
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
IHI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.